“Anti-CD19 Antibody Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anti-CD19 Antibody Market.
The Anti-CD19 Antibody Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Anti-CD19 Antibody Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Anti-CD19 Antibody treatment therapies with a considerable amount of success over the years.
-
Anti-CD19 Antibody companies working in the treatment market are RemeGen, Caribou Biosciences, Precision Biosciences, TG Therapeutics, Xencor, Horizon Therapeutics, Morphosys, and others, are developing therapies for the Anti-CD19 Antibody treatment
-
Emerging Anti-CD19 Antibody therapies in the different phases of clinical trials are- RC58, CB-010, PBCAR19B, TG-1801, Obexelimab (XmAb5871), Inebilizumab, Tafasitamab, and others are expected to have a significant impact on the Anti-CD19 Antibody market in the coming years.
-
In May 2024, ADC Therapeutics released topline Phase II data for its anti-CD19 antibody drug conjugate Zynlonta (loncastuximab tesirine-lpyl), showing high treatment response rates in patients with relapsed or refractory marginal zone lymphoma. The early data, from 15 evaluable patients out of 50 enrolled in the single-arm, open-label mid-stage study, revealed that 13 patients achieved complete response (CR) and one patient demonstrated partial response. All responses were maintained until the data cut-off.
-
In December 2023, Researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center have reported early results from a Phase I clinical trial of AT101, a novel CAR T cell therapy. This therapy, which employs a unique binding mechanism to target CD19, demonstrated a 100 percent complete response (CR) rate at higher dose levels in the trial.
Anti-CD19 Antibody Overview
An anti-CD19 antibody refers to a type of monoclonal antibody that specifically targets and binds to CD19, a protein found on the surface of B cells. CD19 is involved in the activation, proliferation, and differentiation of B cells, which play a critical role in the immune response by producing antibodies.
Get a Free Sample PDF Report to know more about Anti-CD19 Antibody Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/anti-cd19-antibody-pipeline-insight
Emerging Anti-CD19 Antibody Drugs Under Different Phases of Clinical Development Include:
-
RC58: RemeGen
-
CB-010: Caribou Biosciences
-
PBCAR19B: Precision Biosciences
-
TG-1801: TG Therapeutics
-
Obexelimab (XmAb5871): Xencor
-
Inebilizumab: Horizon Therapeutics
-
Tafasitamab: Morphosys
Anti-CD19 Antibody Route of Administration
Anti-CD19 Antibody pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Anti-CD19 Antibody Molecule Type
Anti-CD19 Antibody Products have been categorized under various Molecule types, such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Anti-CD19 Antibody Pipeline Therapeutics Assessment
-
Anti-CD19 Antibody Assessment by Product Type
-
Anti-CD19 Antibody By Stage and Product Type
-
Anti-CD19 Antibody Assessment by Route of Administration
-
Anti-CD19 Antibody By Stage and Route of Administration
-
Anti-CD19 Antibody Assessment by Molecule Type
-
Anti-CD19 Antibody by Stage and Molecule Type
DelveInsight’s Anti-CD19 Antibody Report covers around products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Anti-CD19 Antibody product details are provided in the report. Download the Anti-CD19 Antibody pipeline report to learn more about the emerging Anti-CD19 Antibody therapies
Some of the key companies in the Anti-CD19 Antibody Therapeutics Market include:
Key companies developing therapies for Anti-CD19 Antibody are – TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others.
Anti-CD19 Antibody Pipeline Analysis:
The Anti-CD19 Antibody pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Anti-CD19 Antibody with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anti-CD19 Antibody Treatment.
-
Anti-CD19 Antibody key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Anti-CD19 Antibody Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anti-CD19 Antibody market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Anti-CD19 Antibody drugs and therapies
Anti-CD19 Antibody Pipeline Market Drivers
-
High incidence rates of B-cell malignancies, rise in healthcare investment (by the government and private organizations) are some of the important factors that are fueling the Anti-CD19 Antibody Market.
Anti-CD19 Antibody Pipeline Market Barriers
-
However, side effects associated with the Treatment, high cost associated with the Treatment and other factors are creating obstacles in the Anti-CD19 Antibody Market growth.
Scope of Anti-CD19 Antibody Pipeline Drug Insight
-
Coverage: Global
-
Key Anti-CD19 Antibody Companies: RemeGen, Caribou Biosciences, Precision Biosciences, TG Therapeutics, Xencor, Horizon Therapeutics, Morphosys, and others
-
Key Anti-CD19 Antibody Therapies: RC58, CB-010, PBCAR19B, TG-1801, Obexelimab (XmAb5871), Inebilizumab, Tafasitamab, and others
-
Anti-CD19 Antibody Therapeutic Assessment: Anti-CD19 Antibody current marketed and Anti-CD19 Antibody emerging therapies
-
Anti-CD19 Antibody Market Dynamics: Anti-CD19 Antibody market drivers and Anti-CD19 Antibody market barriers
Request for Sample PDF Report for Anti-CD19 Antibody Pipeline Assessment and clinical trials
Table of Contents
1. Anti-CD19 Antibody Report Introduction
2. Anti-CD19 Antibody Executive Summary
3. Anti-CD19 Antibody Overview
4. Anti-CD19 Antibody- Analytical Perspective In-depth Commercial Assessment
5. Anti-CD19 Antibody Pipeline Therapeutics
6. Anti-CD19 Antibody Late Stage Products (Phase II/III)
7. Anti-CD19 Antibody Mid Stage Products (Phase II)
8. Anti-CD19 Antibody Early Stage Products (Phase I)
9. Anti-CD19 Antibody Preclinical Stage Products
10. Anti-CD19 Antibody Therapeutics Assessment
11. Anti-CD19 Antibody Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Anti-CD19 Antibody Key Companies
14. Anti-CD19 Antibody Key Products
15. Anti-CD19 Antibody Unmet Needs
16 . Anti-CD19 Antibody Market Drivers and Barriers
17. Anti-CD19 Antibody Future Perspectives and Conclusion
18. Anti-CD19 Antibody Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: India
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services